You are here

TGA Internet site archive

The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.

Cost recovery implementation statement, V1.3

Version 1.3 March 2018

8 April 2018

Book pagination

Appendix 1 - Financial performance by industry sector group

1. Prescription medicines

Volumes[4] 2015-16
Actual
2016-17
Actual
2017-18
Budget
2018-19
Estimate
2019-20
Estimate
Biological prescription medicines 580 501 486 486 486
Non-biological prescription medicines - higher charge 522 522 493 493 493
Non-biological prescription medicines - lower charge 6,536 5,888 5,640 5,640 5,640
Revenue and expenses 2015-16
Actual
$'m
2016-17
Actual
$'m
2017-18
Budget
$'m
2018-19
Estimate
$'m
2019-20
Estimate
$'m
A: Revenue
Cost recovery revenue 71.7 68.5 71.2 73.2 74.3
Total A 71.7 68.5 71.2 73.2 74.3
B: Expenses
Direct 36.9 40.0 41.8 43.1 43.7
Indirect 26.3 28.3 29.8 30.7 31.2
Total B 63.2 68.4 71.6 73.8 74.9
Surplus (deficit) 8.5 0.1 (0.4) (0.6) (0.6)

Footnotes

  1. Number of entries on the ARTG subject to the annual charge.
  2. Following the internal organisation restructure (industry sector based) within the TGA, a new activity based costing model has been developed in 2016-17 based on a staff effort survey undertaken in 2016-17. The allocation of direct and indirect expenses is based on the ratio from the most recent 2016-17 model. The TGA will continue to review the costing model and apply changes when necessary.

2. Over the counter mediciness

Volumes[6] 2015-16
Actual
2016-17
Actual
2017-18
Budget
2018-19
Estimate
2019-20
Estimate
Over the counter medicines 2,667 2,441 2,417 2,417 2,417
Revenue and expenses 2015-16
Actual
$'m
2016-17
Actual
$'m
2017-18
Budget
$'m
2018-19
Estimate
$'m
2019-20
Estimate
$'m
A: Revenue
Cost recovery revenue 6.7 7.8 7.9 8.1 8.3
Total A 6.7 7.8 7.9 8.1 8.3
B: Expenses[7]
Direct 2.8 3.0 3.1 3.2 3.3
Indirect 2.3 2.6 2.6 2.7 2.8
Total B 5.1 5.7 5.8 6.0 6.1
Surplus (deficit) 1.6 2.2 2.1 2.2 2.2

Footnotes

  1. Number of entries on the ARTG subject to the annual charge.
  2. Following the internal organisation restructure (industry sector based) within the TGA, a new activity based costing model has been developed in 2016-17 based on a staff effort survey undertaken in 2016-17. The allocation of direct and indirect expenses is based on the ratio from the most recent 2016-17 model. The TGA will continue to review the costing model and apply changes when necessary.

3. Complementary mediciness

Volumes[8] 2015-16
Actual
2016-17
Actual
2017-18
Budget
2018-19
Estimate
2019-20
Estimate
Registered complementary medicines 132 131 133 133 133
Listed complementary medicines 11,003 10,052 10,238 10,238 10,238
Revenue and expenses 2015-16
Actual
$'m
2016-17
Actual
$'m
2017-18
Budget
$'m
2018-19
Estimate
$'m
2019-20
Estimate
$'m
A: Revenue
Cost recovery revenue 15.7 13.8 14.3 14.7 14.9
Total A 15.7 13.8 14.3 14.7 14.9
B: Expenses[9]
Direct 7.2 7.3 8.1 8.4 8.5
Indirect 5.2 5.6 5.9 6.1 6.2
Total B 12.4 12.9 14.0 14.5 14.7
Surplus (deficit) 3.3 0.9 0.3 0.2 0.3

Footnotes

  1. Number of entries on the ARTG subject to the annual charge.
  2. Following the internal organisation restructure (industry sector based) within the TGA, a new activity based costing model has been developed in 2016-17 based on a staff effort survey undertaken in 2016-17. The allocation of direct and indirect expenses is based on the ratio from the most recent 2016-17 model. The TGA will continue to review the costing model and apply changes when necessary.

4. Medical devices, including in-vitro diagnostic (IVD) devicess

Volumes[10] 2015-16
Actual
2016-17
Actual
2017-18
Budget
2018-19
Estimate
2019-20
Estimate
Included medical devices 44,878 45,267 45,471 45,471 45,471
IVD medical devices N/A N/A 2,492 2,492 2,492
Other therapeutic goods 359 294 279 279 279
Revenue and expenses 2015-16
Actual
$'m
2016-17
Actual
$'m
2017-18
Budget
$'m
2018-19
Estimate
$'m
2019-20
Estimate
$'m
A: Revenue
Cost recovery revenue 34.3 37.2 36.8 37.8 38.4
Total A 34.3 37.2 36.8 37.8 38.4
B: Expenses[11]
Direct 17.1 19.6 19.4 20.0 20.3
Indirect 12.2 13.8 13.8 14.3 14.5
Total B 29.4 33.3 33.3 34.3 34.8
Surplus (deficit) 4.9 3.9 3.5 3.5 3.6

Footnotes

  1. Number of entries on the ARTG subject to the annual charge.
  2. Following the internal organisation restructure (industry sector based) within the TGA, a new activity based costing model has been developed in 2016-17 based on a staff effort survey undertaken in 2016-17. The allocation of direct and indirect expenses is based on the ratio from the most recent 2016-17 model. The TGA will continue to review the costing model and apply changes when necessary.

5. Good manufacturing practicess

Volumes[12] 2015-16
Actual
2016-17
Actual
2017-18
Budget
2018-19
Estimate
2019-20
Estimate
Low level GMP licence 105 112 111 111 111
High level GMP licence 163 163 161 161 161
Revenue and expenses 2015-16
Actual
$'m
2016-17
Actual
$'m
2017-18
Budget
$'m
2018-19
Estimate
$'m
2019-20
Estimate
$'m
A: Revenue
Cost recovery revenue 11.2 9.9 10.5 10.8 11.0
Total A 11.2 9.9 10.5 10.8 11.0
B: Expenses[13]
Direct 7.8 8.7 8.8 9.1 9.2
Indirect 5.4 5.7 6.1 6.3 6.4
Total B 13.2 14.4 14.9 15.4 15.6
Surplus (deficit) (2.0) (4.4) (4.4) (4.6) (4.6)

Footnotes

  1. Number of entries on the ARTG subject to the annual charge.
  2. Following the internal organisation restructure (industry sector based) within the TGA, a new activity based costing model has been developed in 2016-17 based on a staff effort survey undertaken in 2016-17. The allocation of direct and indirect expenses is based on the ratio from the most recent 2016-17 model. The TGA will continue to review the costing model and apply changes when necessary.

6. Blood, blood components and biologicalss

Volumes[14] 2015-16
Actual
2016-17
Actual
2017-18
Budget
2018-19
Estimate
2019-20
Estimate
Blood primary site 5 5 5 5 5
Blood secondary site 79 81 75 75 75
Single step manufacturer of human tissue 24 18 17 17 17
Class 2 biological products 20 20 19 19 19
Class 3 biological products 5 6 6 6 6
Revenue and expenses 2015-16
Actual
$'m
2016-17
Actual
$'m
2017-18
Budget
$'m
2018-19
Estimate
$'m
2019-20
Estimate
$'m
A: Revenue
Cost recovery revenue 2.2 2.6 2.5 2.6 2.6
Total A 2.2 2.6 2.5 2.6 2.6
B: Expenses[15]
Direct 1.6 2.0 1.8 1.9 1.9
Indirect 1.3 1.6 1.4 1.5 1.5
Total B 2.9 3.6 3.2 3.3 3.4
Surplus (deficit) (0.6) (0.9) (0.7) (0.8) (0.8)

Footnotes

  1. Number of entries on the ARTG subject to the annual charge.
  2. Following the internal organisation restructure (industry sector based) within the TGA, a new activity based costing model has been developed in 2016-17 based on a staff effort survey undertaken in 2016-17. The allocation of direct and indirect expenses is based on the ratio from the most recent 2016-17 model. The TGA will continue to review the costing model and apply changes when necessary.

7. Other activitiess

Revenue and expenses 2015-16
Actual
$'m
2016-17
Actual
$'m
2017-18
Budget
$'m
2018-19
Estimate
$'m
2019-20
Estimate
$'m
A: Revenue
Revenue 2.0 1.7 1.7 1.7 1.7
Total A 2.0 1.7 1.7 1.7 1.7
B: Expenses
Other Expense 2.0 2.7 2.0 1.7 1.7
MMDR Expense N/A 6.9 3.6 N/A N/A
Total B 2.0 8.6 5.6 1.7 1.7
Surplus (deficit) 0.0 (6.9) (4.0) 0.0 0.0

Book pagination